FEATURES OF CANCER STEM CELLS DISTRIBUTION IN DIFFERENT IMMUNOHISTOCHEMICAL SUBTYPES OF INVASIVE BREAST CARCINOMAS
DOI: 10.22138/2500-0918-2018-15-3-413-420
A.A. Brilliant, Y.M. Brilliant, S.V. Sazonov
Institute of Medical Cell Technologies, Yekaterinburg, Russian Federation;
Ural State Medical University, Yekaterinburg, Russian Federation
Abstract. The aim of the research was to study the pool of cancer stem cells in different immunohistochemicl subtypes of breast cancer. Material and methods: the material of 110 cases of infiltrative breast carcinoma was used. For detection of cancer cells in cancer population the presence of ALDH1A1 protein was explored. In all cases expression of ER, PR, HER-2/neu and Ki-67 was studied for division to immunohistochemical subtypes. Immunohistochemical method was used. Results: in group with high content of cancer stem cells cases of Hormone-receptor-negative HER-2 positive and Triple negative subtypes were dominated (46 and 37% respectively). These subtypes are thought to be the most adverse to prognosis and answer to chemotherapy. 96% of cases of Luminal A and 100% of cases of Luminal B subtypes contained non-significant number of cancer stem cells in the cancer pool. The highest number cases, in which more than 10% cancer stem cells in the general cancer pool was found, related to Hormone-receptor negative HER-2 positive (20%), Hormone-receptor positive HER-2 positive (12%) and Triple negative (17%) subtypes. Wherein all the cases of the last group with the high level of ALDH1A1 expression contained more than 50% cancer stem cells in the general pool. Conclusion: it was found that ratio of cases of different immunohistochemical subtypes differed in groups with low and high content of cancer stem cells.
Keywords: breast cancer, cancer stem cells, ALDH
Received 03.05.2018
For citation:
Brilliant A.A., Brilliant Y.M., Sazonov S.V. Features of cancer stem cells distribution in different immunohistochemical subtypes of invasive breast carcinomas. Vestn. Ural. Med. Akad. Nauki. = Journal of Ural Medical Academic Science. 2018, Vol. 15, no. 3, pp. 413–420. DOI: 10.22138/2500-0918-2018-15-3-413-420 (In Russ)
REFERENCES
1. Reya T. ,Morrison S.J., Carke M.F., et al. Stem cells,cancer, and cancer stem cells. Nature 2001; 414: 105-11. doi: 10.1038/35102167
2. Yastrebov A.P., Grebnev D.Y., Maklakova I.Y. The stem cells, their properties, and the sources of the role in regenerative medicine [Stvolovie kletki, ih raznovidnosti i roli v regenerativnoi meditcine]. Ekaterinburg, 2016, (In Russ.).
3. Jinesh G., Willis D.L., Kamat A.M. Bladder Cancer Stem Cells: Biological and Therapeutic Perspectives. Current Stem Cell Research & Therapy 2014; 9(2):1-13. doi: 10.1158/0008-5472.CAN-05-2018
4. Al-Hajj M., Wicha M.S., Benito-Hernandez A., et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983–8. doi: 10.1073/pnas.0530291100
5. Ginestier C., Hur M.H., Charafe-Jauffret E., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555–67. doi: 10.1016/j.stem.2007.08.014
6. Pearce D.J., Taussig D., Simpson C., et al. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 2005; 23(6):752-60. doi: 10.1634/stemcells.2004-0292
7. Ginestier C., Hur M.H., Charafe-Jauffret E., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007; 1(5): 555–567. doi: 10.1016/j.stem.2007.08.014
8. Morimoto K., Kim S.J., Tanei T., et al. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci. 2009; 100(6):1062-8. doi: 10.1111/j.1349-7006.2009.01151
9. Sazonov S. V., Brilliant A. A., Dorofeev A.V., Demidov S. M. Some regularities of Estrogen, Progesterone Receptor and Ki-67 expression on tumor cells of breast carcinoma. Ural medical journal. 2010. Vol. 77. No. 12. Р. 68. (In Russ.).
10. Brilliant A.A., Sazonov S.V. Changing the receptor status Group proliferative activity of breast carcinomas [Izmenenie statusa receptorov b proliferativnoi aktivnosti karcinome grudi]. Herald of Ural Medical Academic Science [Vestnik ural'skoi meditsinskoi akademicheskoi nauki]. 2013, no. 1 (43), pp. 61-63 (In Russ.).
11. Mnichovich M.V., Midib K.Yu., Galliamova A.R., et al. Immunohistochemical evaluation of cadherin-catenin complex expression in breast cancer. Journal of Anatomy and Histopathology. 2017. T.6. №1. P.63-68. (In Russ.). doi: 10.18499/2225-7357-2017-6-1-63-68
12. Semiglazov V.F., Paltuev R.M., Semiglazov V.V., Dashyan G.A., Semiglazova T.Y., Krivorotko P.V., Nikolaev K.S. General St. Gallen-2015 guidelines for the treatment of early breast cancer (adapted by the experts of the Russian Society of Breast Oncologists). Women Reproductive System Tumors. 2015;11(3):43-60. (In Russ.) doi:10.17650/1994-4098-2015-11-3-43-60
Authors
Aleksandr A. Brilliant
Institute of Medical Cell Technologies
PhD (Biol.), Senior Reseacher
Russian Federation, 620026, Ekaterinburg, ul. Karl Marx, 22а
alex_brilliant@mail.ru
Yulia M. Brilliant
Institute of Medical Cell Technologies
PhD (Med.), Senior Researcher
Russian Federation, 620026, Ekaterinburg, ul. Karl Marx, 22а
yulkat@bk.ru
Sergey V. Sazonov
Institute of Medical Cell Technologies
Dr. Sci. (Med.), Professor, Head of the Department of Histology, Cytology and Embryology
Russian Federation, 620026, Ekaterinburg, ul. Karl Marx, 22а
prof-ssazonov@yandex.ru